Surrozen Inc (SRZN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $602.54M
Last updated: Nov 17, 2026 at 11:06 AM ET
Surrozen Inc (SRZN) Stock Forecast
Analysts expect Surrozen (SRZN) to earn -$18.78 per share in the fiscal year ending Dec 31, 2026, on revenue of $10.20M. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$4.71.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 6 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 92.2%.
- Fiscal year ending Dec 31, 2026
- -$18.78
- EPS consensus, revenue $10.20M
- Fiscal year ending Dec 31, 2027
- -$4.71
- EPS consensus, revenue $800000
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$18.78 | -$18.78 to -$18.78 | 1 | $10.20M | $10.00M to $11.00M | 5 |
| Dec 31, 2027 | -$4.71 | -$5.19 to -$3.93 | 3 | $800000 | N/A | 5 |
Quarterly Estimates
The EPS consensus falls from -$0.95 for the quarter ending Dec 31, 2026 to -$1.00 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.95 | -$1.28 to -$0.64 | 8 | $484500 | N/A | 6 |
| Mar 31, 2027 | -$1.00 | -$1.03 to -$0.97 | 2 | $500000 | N/A | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$9.14.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$18.78 | -$9.14 | -$9.14 | -$9.14 | -$9.14 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.71 | -$4.19 | -$4.19 | -$4.19 | -$4.58 | N/A |
| Quarter ending Mar 31, 2027 | -$1.00 | -$0.87 | -$0.87 | -$0.87 | -$0.86 | N/A |
Frequently Asked Questions About SRZN
What is the SRZN stock forecast?
Consensus analyst estimates put Surrozen's EPS at -$18.78 for the fiscal year ending Dec 31, 2026, on revenue of $10.20M. The consensus rating from 6 analysts is Buy.
How do analysts rate SRZN stock?
Of 6 analysts covering Surrozen, 0 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from SRZN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$18.78, with estimates from -$18.78 to -$18.78 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.71, with estimates from -$5.19 to -$3.93 from 3 analysts.
What revenue do analysts expect from Surrozen next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $10.20M, with estimates from $10.00M to $11.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $800000.
How many analysts cover SRZN?
6 analysts rate Surrozen stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
SRZN pages: Overview, Earnings, Forecast, Financials, Competitors